Coagulation as a pharmacodynamic biomarker in breast cancer: Changes in tumour expression of extrinsic clotting factors in response to breast cancer treatment

Introduction: Short-term treatment of estrogen receptor (ER) positive early breast cancer with aromatase inhibitors inhibits proliferation in approximately 80% of early breast cancers, as evidenced by reduction in Ki67. POETIC is a phase III randomised (2:1, AI:control) trial for post-menopausal women with ER-positive early breast cancer to determine whether two weeks of perioperative AI therapy improves outcome compared with standard adjuvant therapy alone. In a sub-study of POETIC the effect of AI treatment on systemic and tumour coagulation markers was determined.

Source: Thrombosis Research - April 1, 2018 Category: Hematology Authors: J. Castle, S. Pritchard, M. Dowsett, N.J. Bundred, C.C. Kirwan Source Type: research